Leading Psilocybin Research
Since 2015 we’ve been leading the way in psilocybin research and our partnership with the University of Guelph is another step in that journey. We’re the world’s first legal exporter of psilocybin and provide high quality biomass to research institutions around the world. This partnership shows our commitment to psilocybin research and our role in developing new treatments.
We’re stoked to be partnering with the University of Guelph to research how psilocybin can help the adolescent brain with autism. This is the first of its kind, we’re looking at how specific strains of psilocybin, legally imported from Jamaica, can be used to support those with Autism Spectrum Disorders (ASD). We’re looking at the chemical diversity of our mushrooms and testing them in a rodent model to see what’s possible in mental health.
High Quality Research
We’re partnering with the University of Guelph to get to the bottom of psilocybin’s benefits. The research will break down the chemical composition of our psilocybin mushrooms. Over 12 months they’ll identify and standardize all the compounds in these mushrooms.
Mental Health Innovation
We’re taking mental health research to the next level. With the research team, we’ll be looking at how psilocybin affects the adolescent brain. Using cutting edge research methods, this study will examine how microdoses of psilocybin impact brain function and behaviour. This could lead to new treatments for ASD where traditional therapies have failed.
Neuropsychopharmacology
As we are working with the University of Guelph on the adolescent brain and using advanced methods to study psilocybin, the study will also look at how microdoses of psilocybin affect brain function and behaviour and will inform future therapeutic applications in neuropsychopharmacology. This is a big step in our continued work to understand and use psilocybin responsibly.